The infections include Complicated Intra-Abdominal Infections (cIAI) and Complicated Urinary Tract Infections (cUTI).
CAZ-AVI comprises cephalosporin (ceftazidime) and a novel beta-lactamase inhibitor (avibactam), which helps overcome antibiotic-resistance and treat the infections resistant to existing therapies.
This study comprises two separate CAZ-AVI phase II trials.
The cIAI Phase II trial showed that the efficacy of CAZ-AVI given with metronidazole in adult patients was similar to meropenem, a treatment given to patients with Complicated Intra-Abdominal Infections.
The cUTI Phase II trial showed that the efficacy of CAZ-AVI in adult patients was similar to imipenem cilastatin, which is given to patients with Complicated Urinary Tract Infections.